Acrivon Therapeutics, Inc. - ACRV
Ownership (Schedule 13D / 13G) · latest 50 filings
· Back to all files
Visible: 0
| Filed | Form | Reporting person | Percent | Shares | SEC |
|---|---|---|---|---|---|
| Mar 23, 2026 | SCHEDULE 13D/A | — | — | — | View |
| Nov 21, 2025 | SCHEDULE 13G | Citadel Advisors LLC | 4.9% | 1,541,326 | View |
| Nov 21, 2025 | SCHEDULE 13G | Citadel Advisors Holdings LP | 4.9% | 1,541,326 | View |
| Nov 21, 2025 | SCHEDULE 13G | Citadel GP LLC | 4.9% | 1,541,326 | View |
| Nov 21, 2025 | SCHEDULE 13G | Citadel Securities LLC | 0.6% | 180,541 | View |
| Nov 21, 2025 | SCHEDULE 13G | Citadel Securities Group LP | 0.6% | 180,541 | View |
| Nov 21, 2025 | SCHEDULE 13G | Citadel Securities GP LLC | 0.6% | 180,541 | View |
| Nov 21, 2025 | SCHEDULE 13G | Kenneth Griffin | 5.5% | 1,721,867 | View |
| Nov 14, 2025 | SCHEDULE 13G/A | Citadel Advisors LLC | 4.9% | 1,541,326 | View |
| Nov 14, 2025 | SCHEDULE 13G/A | Citadel Advisors Holdings LP | 4.9% | 1,541,326 | View |
| Nov 14, 2025 | SCHEDULE 13G/A | Citadel GP LLC | 4.9% | 1,541,326 | View |
| Nov 14, 2025 | SCHEDULE 13G/A | Citadel Securities LLC | 0.0% | 39 | View |
| Nov 14, 2025 | SCHEDULE 13G/A | Citadel Securities Group LP | 0.0% | 39 | View |
| Nov 14, 2025 | SCHEDULE 13G/A | Citadel Securities GP LLC | 0.0% | 39 | View |
| Nov 14, 2025 | SCHEDULE 13G/A | Kenneth Griffin | 4.9% | 1,541,365 | View |
Percent = "% of class represented by amount beneficially owned" for this reporting person in the filed 13D/13G.
Shares = reported beneficial ownership amount for the same row (not portfolio shares from 13F).
Amendments (/A) can repeat the same holder over time, so rows should not be summed.
Extraction is best-effort from filing text and can be missing or noisy; verify exact figures via the SEC link in each row.